Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia

2003 ◽  
Vol 30 (2) ◽  
pp. 282-285 ◽  
Author(s):  
N.C. Munshi ◽  
B. Barlogie
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
High Dose ◽  
Waldenström’S Macroglobulinemia ◽  
High Dose Therapy ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Waldenström's Macroglobulinemia ◽  
Cell Support

scholarly journals Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma

2012 ◽  
Vol 3 (2) ◽  
pp. 81-88
Author(s):  
Helge Menzel ◽  
Katarzyna Hinmüller ◽  
Hans-Jochem Kolb ◽  
Tibor Schuster ◽  
Alexander Hoellein ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Univariate Analysis ◽  
Progression Free Survival ◽  
High Dose ◽  
High Dose Therapy ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support

Objective: Induction high-dose chemotherapy followed by myeloablative melphalan (HD-Mel) treatment and autologous hematopoietic stem-cell support (autoSCT) is a standard treatment for multiple myeloma (MM) either upfront or in relapse after conventional treatment. We performed a retrospective analysis of consecutive patients undergoing a late repeat HD-Mel/autoSCT treatment for MM. Methods: Data from 24 consecutive patients with MM who underwent a myeloablative treatment with HD-Mel late after completion of upfront first high-dose therapy were assessed for toxicity, response, progression-free survival (PFS) and time to next treatment (TTNT). These data were correlated with the results obtained after the initial high dose therapy and autoSCT. Results: A total of 23 patients were treated with novel drugs (lenalidomide, thalidomide, bortezomib) after relapse to initial autoSCT. The median overall survival (OS) of all patients was 90 months. 19 patients (79%) achieved a very good partial remission (VGPR) or complete remission (CR) after initial autoSCT, compared with 42% after late autoSCT. PFS and TTNT were 19 and 24 months after initial compared with 13 and 21 months after late autoSCT. Univariate analysis identified initial response duration and the achievement of a CR/VGPR after the initial transplantation to be associated with prolonged response after repeat autoSCT. Conclusions: Our data indicate that late high-dose treatment followed by autoSCT is safe and effective after upfront intensive treatment, can bridge to allogeneic SCT, and encourage collection of an additional graft.

Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support

2006 ◽  
Vol 7 (1) ◽  
pp. 73-76 ◽  
Author(s):  
Efstathios Kastritis ◽  
Evangelos Terpos ◽  
Athanasios Anagnostopoulos ◽  
Irini Xilouri ◽  
Meletios Athanasios Dimopoulos
Keyword(s):  
Stem Cell ◽  
Bone Metabolism ◽  
Biochemical Markers ◽  
Poems Syndrome ◽  
High Dose ◽  
High Dose Therapy ◽  
Stem Cell Support ◽  
Dose Therapy ◽  
Cell Support

scholarly journals High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

2006 ◽  
Vol 17 (10) ◽  
pp. 1479-1488 ◽  
Author(s):  
P. Pedrazzoli ◽  
J.A. Ledermann ◽  
J.-P. Lotz ◽  
S. Leyvraz ◽  
M. Aglietta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Solid Tumors ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

1997 ◽  
Vol 15 (5) ◽  
pp. 1870-1879 ◽  
Author(s):  
K H Antman ◽  
P A Rowlings ◽  
W P Vaughan ◽  
C J Pelz ◽  
J W Fay ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Autologous Blood ◽  
Locally Advanced ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
National Cooperative ◽  
Cell Support

PURPOSE To identify trends in high-dose therapy with autologous hematopoietic stem-cell support (autotransplants) for breast cancer (1989 to 1995). PATIENTS AND METHODS Analysis of patients who received autotransplants and were reported to the Autologous Blood and Marrow Transplant Registry. Between January 1, 1989 and June 30, 1995, 19,291 autotransplants were reviewed; 5,886 were for breast cancer. Main outcomes were progression-free survival (PFS) and survival. RESULTS Between 1989 and 1995, autotransplants for breast cancer increased sixfold. After 1992, breast cancer was the most common indication for autotransplant. Significant trends included increasing use for locally advanced rather than metastatic disease (P < .00001) and use of blood-derived rather than marrow-derived stem cells (P < .00001). One-hundred-day mortality decreased from 22% to 5% (P < .0001). Three-year PFS probabilities were 65% (95% confidence intervals [Cls], 59 to 71) for stage 2 disease, and 60% (95% Cl, 53 to 67) for stage 3 disease. In metastatic breast cancer, 3-year probabilities of PFS were 7% (95% Cl, 4 to 10) for women with no response to conventional dose chemotherapy; 13% (95% Cl, 9 to 17) for those with partial response; and 32% (95% Cl, 27 to 37) for those with complete response. Eleven percent of women with stage 2/3 disease and less than 1% of those with stage 4 disease participated in national cooperative group randomized trials. CONCLUSION Autotransplants increasingly are used to treat breast cancer. One-hundred-day mortality has decreased substantially. Three-year survival is better in women with earlier stage disease and in those who respond to pretransplant chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document